Delivery Order SPE2DR25D1103-SPE2DR26FE331
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a contract ceiling value of $5,708.57 and an ultimate completion date of September 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The place of performance is the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on November 3, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a contract ceiling value of $18,957.53. This non-set-aside, competitively awarded delivery order carries a firm fixed price and is scheduled for completion by November 4, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 26, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This order, valued at $15,173.15 with a firm fixed price contract type, is scheduled for completion by September 29, 2025, and will be fulfilled from the company's Conshohocken, Pennsylvania location. The award was competitively procured with no set-aside designation and represents a delivery order against...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 30, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $2,870.86 and is scheduled for completion by July 31, 2025. The award represents a child contract action under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for the supply of Ozempic 1 mg/dose (4 mg/3 mL) injectable medication in 3 mL vials. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $6,076.82 and a completion date of June 3, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract is valued at $3,759.96 and carries a firm fixed price with an ultimate completion date of August 19, 2025. The award utilized competitive procurement procedures with no set-aside designation. The place of performance is identified as the vendor's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,820.04 to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competition. The contract is set to be completed by December 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a contract ceiling value of $5,639.94 and an ultimate completion date of July 14, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 8, 2025, by the Defense Logistics Agency (DLA) for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $20,853.10. This is a firm fixed price, competitively awarded delivery order without set-aside designation, to be fulfilled at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 11, 2025. The delivery order is issued under AmerisourceBergen...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order valued at $36,378.29 for Ozempic 2 mg/dose (8 mg/3 mL) 3 mL vials from the Defense Medical Supply Chain on July 28, 2025. The contract is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, and was awarded on a competitive basis without set-aside designation. This delivery order represents a child contract executed under...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FE331Delivery Order
AmerisourceBergen Drug Corp was awarded a competitive delivery order on December 11, 2025, by the Defense Logistics Agency for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials with a ceiling value of $2,426.72 and a firm fixed price structure. The order is scheduled for ultimate completion by December 12, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million through December 2026, which serves as the prime vehicle for supplying pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp holds a strategic position within the federal medical supply chain, providing a comprehensive portfolio of medications and medical commodities to the Defense Health Agency and other government healthcare systems. The contract received no set-aside designation, indicating it was competitively awarded. Ozempic is a diabetes medication commonly used in military and veteran healthcare systems, and this delivery order represents one of numerous pharmaceutical procurement actions the vendor executes under its expansive DLA contract vehicle, demonstrating the company's capability to meet specialized federal medical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 12/10/25 |